Stock vs Stock Comparison

Johnson & Johnson vs Abbott Laboratories

ABT wins the Tale of the Tape 5–4.

JNJ$223.24
ABT$86.99

🏆 Tale of the Tape

45
JNJABT
28.5%Profitability (Net Margin)14.7%
26.1xValuation (P/E)24.0x
18.3%Efficiency (ROIC)10.1%
4/9Health (Piotroski F)5/9
4.0Safety (Altman Z)4.9
6.0%Growth (Rev YoY)5.7%
2.69Risk (Sharpe 1Y)-1.05
1.44xBalance Sheet (D/E)0.64x
3.25%FCF Yield4.21%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.304
252-Day Correlation
0.153
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricJNJABT
Market Cap$542.4B$149.1B
P/E Ratio26.1x24.0x
Forward P/E17.7x14.1x
P/B6.68x2.86x
Dividend Yield2.38%2.94%
Beta0.260.65

Quantitative Metrics

MetricJNJABT
DCF Fair Value$134.24$57.20
DCF Upside-43.6%-43.2%
Piotroski F4/95/9
Altman Z3.974.87
Beneish M-2.27-2.53
FCF Yield3.25%4.21%
Net Debt/EBITDA0.5x0.1x
ROIC18.3%10.1%
WACC7.7%9.4%
ROIC – WACC10.5pp0.7pp
Gross Margin67.9%56.4%
Net Margin28.5%14.7%
Rev Growth YoY6.0%5.7%
Sharpe (1Y)2.69-1.05
Max Drawdown 3Y-16.0%
FCF Payout Ratio64%56%

JNJ Price

Loading chart...

ABT Price

Loading chart...

ETF Exposure

JNJ found in:

XLV10.42%
IYH10.14%
VHT8.84%
HDV6.84%
MTUM3.76%
DIA2.83%
MGV2.75%
DGRO2.64%
VIG2.49%
VYM2.30%
VTV2.16%
DGRW2.02%
SCHV2.02%
IWD1.94%
QUS1.81%
XPH1.74%
VONV1.69%
NOBL1.58%
VFMV1.42%
VFMO1.02%
SCHX0.96%
SPYG0.94%
SDY0.93%
VOO0.90%
SCHB0.90%
SPY0.87%
IVV0.85%
VONE0.84%
SPTM0.81%
VTI0.80%
SPYV0.79%
SPLG0.76%
ITOT0.75%
URTH0.70%
ACWI0.57%
VT0.49%
RSP0.21%
VFVA0.15%
ONEO0.05%

ABT found in:

IHI16.06%
IYH2.88%
XLV2.85%
VHT2.55%
DGRW1.71%
XHE1.36%
NOBL1.34%
SDY0.99%
MGV0.78%
VIG0.71%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.61%
IWD0.58%
QUS0.57%
SPYV0.53%
VONV0.48%
IVV0.37%
SPLG0.37%
ESGV0.36%
ITOT0.33%
SCHX0.33%
SCHB0.30%
VOO0.26%
VONE0.24%
SPY0.24%
URTH0.24%
VTI0.23%
SPTM0.22%
ACWI0.20%
RSP0.17%
VT0.14%
ONEO0.08%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

JNJ vs ABT: Head-to-Head Analysis

Johnson & Johnson (JNJ) and Abbott Laboratories (ABT) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ABT leads 5–4 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, JNJ generates a return on invested capital (ROIC) of 18.3% compared to ABT's 10.1%. This suggests JNJ is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between JNJ and ABT is 0.304, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

JNJ appears in 39 ETFs tracked by SecuritiesDB, while ABT appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, JNJ or ABT?

Our quantitative analysis compares JNJ and ABT across nine fundamental dimensions. ABT wins the Tale of the Tape 5–4. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are JNJ and ABT correlated?

The 252-day correlation between JNJ and ABT is 0.304. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.